Redeye maintains its positive view of Xspray following yesterday's announcement of a signed a term sheet with Pharmacare Premium regarding manufacturing of its amorphous protein kinase inhibitors (PKIs). Together with the existing production facility in Italy, we believe Xspray will be able to produce its HyNap-products in a commercial scale, as well as maintain development of new candidates at a high pace to secure future growth.